Rose Kushner Award Winners Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

BETHESDA, Md-The American Medical Writers Association (AMWA) has announced the winners of the 1995 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer, sponsored by the AMWA and Zeneca Pharmaceuticals.

BETHESDA, Md-The American Medical Writers Association (AMWA) hasannounced the winners of the 1995 Rose Kushner Awards for WritingAchievement in the Field of Breast Cancer, sponsored by the AMWAand Zeneca Pharmaceuticals.

  • Lay articles: Laurie Tarkan, How Daughters Face Their Mother'sBreast Cancer (McCall's), and Nicole Spelhaug, Breast Cancer:New Perspectives Can Replace Unrealistic Fears (supplement tothe Mayo Clinic Health Letter).
  • Scientific articles: Amy S. Langer and Karen Hassey Dow, TheBreast Cancer Advocacy Movement and Nursing (Oncology Nursing).
  • Scripts: Jane Glenn Haas, On-Line (The Orange Count News Channel).
  • Brochures and monographs: Aaron Rachel Rose, For Single WomenWith Breast Cancer (Y-ME National Breast Cancer Organization).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content